{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:11Z","timestamp":1787595731966,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40259-024-00666-1","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T08:02:06Z","timestamp":1719475326000},"page":"601-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Helen W.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merta","family":"Cushing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-8212","authenticated-orcid":false,"given":"Lisa","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf R.","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0014-2431","authenticated-orcid":false,"given":"Rita L.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"666_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2018.00163","volume":"8","author":"TM Pierpont","year":"2018","unstructured":"Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the world\u2019s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. https:\/\/doi.org\/10.3389\/fonc.2018.00163. (Published 2018 Jun 4).","journal-title":"Front Oncol"},{"issue":"11","key":"666_CR2","first-page":"698","volume":"19","author":"A Major","year":"2021","unstructured":"Major A, Smith SM. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? Clin Adv Hematol Oncol. 2021;19(11):698\u2013709.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"8","key":"666_CR3","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/cncr.20956","volume":"103","author":"JC Hornberger","year":"2005","unstructured":"Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer. 2005;103(8):1644\u201351. https:\/\/doi.org\/10.1002\/cncr.20956.","journal-title":"Cancer"},{"issue":"12","key":"666_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1200\/JCO.2017.77.4893","volume":"36","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Balaban E, Diaz M, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36(12):1260\u20135. https:\/\/doi.org\/10.1200\/JCO.2017.77.4893.","journal-title":"J Clin Oncol"},{"key":"666_CR5","unstructured":"Biosimilar Product Information. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information. Accessed Aug 7, 2022."},{"key":"666_CR6","unstructured":"TRUXIMA [Package Insert]. Yeonsu-gu, Incheon: CELLTRION, Inc; 2018."},{"issue":"11","key":"666_CR7","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","volume":"5","author":"M Ogura","year":"2018","unstructured":"Ogura M, Sancho JM, Cho SG, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018;5(11):e543\u201353. https:\/\/doi.org\/10.1016\/S2352-3026(18)30157-1.","journal-title":"Lancet Haematol."},{"key":"666_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/BTT.S124476","volume":"11","author":"JR Tesser","year":"2017","unstructured":"Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017;11:5\u201311. https:\/\/doi.org\/10.2147\/BTT.S124476. (Published 2017 Feb 17).","journal-title":"Biologics"},{"issue":"3","key":"666_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40259-024-00649-2","volume":"38","author":"NM Sani","year":"2024","unstructured":"Sani NM, Aziz Z, Kamarulzaman A. Use of biosimilars: a systematic review of published position statements and recommendations from health organisations and societies. BioDrugs. 2024;38(3):405\u201323. https:\/\/doi.org\/10.1007\/s40259-024-00649-2. (Epub 2024 Mar 12).","journal-title":"BioDrugs"},{"issue":"1","key":"666_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1855\/jmcp.2019.25.1.102","volume":"25","author":"E Leonard","year":"2019","unstructured":"Leonard E, Wascovich, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102\u201312. https:\/\/doi.org\/10.1855\/jmcp.2019.25.1.102.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"666_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"key":"666_CR12","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed Oct 27, 2023."},{"issue":"4","key":"666_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342. https:\/\/doi.org\/10.1056\/NEJMoa011795.","journal-title":"N Engl J Med"},{"issue":"15","key":"666_CR14","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1182\/bloodadvances.2021004295","volume":"5","author":"M Brink","year":"2021","unstructured":"Brink M, Kahle XU, Vermaat JSP, et al. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Adv. 2021;5(15):2958\u201364. https:\/\/doi.org\/10.1182\/bloodadvances.2021004295.","journal-title":"Blood Adv"},{"key":"666_CR15","unstructured":"POLIVY [Package Insert]. South San Francisco, CA: Genentech, Inc; 2019."},{"key":"666_CR16","unstructured":"MONJUVI [Package Insert]. Boston, MA: MORPHOSYS US, Inc; 2020."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00666-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T02:17:52Z","timestamp":1721009872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00666-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00666-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"4 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H.W.W., V.H.N., T.Y.M., F.N., M.C., M.L., S.L.H., L.L., A.R.A., and R.L.H. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Competing Interests"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available as the data are the property of the health plan and medical groups but are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The institutional review boards (IRBs) of the institutions have reviewed and approved the study (KPNC IRB#1953521 8 Nov 2022 and KPSC IRB #13373 3 Nov 2022). The requirement for informed consent was waived owing to retrospective nature of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. An IRB waiver of informed consent was granted.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"H.W.W. and V.H.N. wrote the first draft of the manuscript; all authors critically reviewed the manuscript for content and approved the final version for submission; T.Y.M., R.L.H., H.W.W., and V.H.N. designed the study. T.Y.M., F.N., H.W.W., and V.H.N. performed data collection; H.W.W., V.H.N., T.Y.M., R.L.H., and F.N. analyzed the data. All authors performed data interpretation.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}